Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-fluorouracil + Corynebacterium parvum
- Development stage
- Unknown
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Administration
- Intravenous, Intramuscular, Subcutaneous, Intratumoral, Intracavitary
01
Overview
This is a combination therapy consisting of 5-fluorouracil (5-FU), a widely used antimetabolite chemotherapy agent, and Corynebacterium parvum, a bacterial immunostimulant. - **5-Fluorouracil** acts as an antimetabolite by inhibiting thymidylate synthase, thereby interfering with DNA synthesis and cell division in rapidly proliferating cancer cells[6][7]. - **Corynebacterium parvum** is used as an immunopotentiator; it stimulates the immune system non-specifically to enhance anti-tumor responses. The rationale for combining these agents is to leverage both direct cytotoxic effects on tumor cells (from 5-FU) and immune-mediated anti-tumor activity (from C. parvum)[1][7]. Clinical studies have evaluated this combination in advanced cancers such as colorectal carcinoma and breast cancer. However, results have shown limited or no additional therapeutic benefit over chemotherapy alone in some settings[7], while other studies suggest possible enhancement of tumor inhibition depending on the chemotherapeutic partner[1].
- Other names
- 5-FU + Corynebacterium parvum5-fluorouracil and Corynebacterium parvumfluorouracil + Corynebacterium parvum
02
Targets
DNADHO (Dihydroorotase)PRR (Pattern recognition receptors)SSB (Single-stranded DNA-binding protein)TS (Thymidylate synthase)
Beyond the preview
Go deeper on 5-fluorouracil + Corynebacterium parvum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5-fluorouracil + Corynebacterium parvum.